All references in this report to ZyVersa, the Company, we, us, or our mean ZyVersa Therapeutics, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Company Overview We are a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients quality of life. We hav...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014271 | EDGAR | 55K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000862 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001493152-24-011073 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010259 | EDGAR | — |
| 2022-04-15 | 2021-12-31 | 0001213900-22-019895 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001493152-25-024263 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023342 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001641172-25-009724 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045351 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001493152-24-031002 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019517 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041185 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001493152-23-029603 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016480 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072377 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001213900-22-048196 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026061 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001493152-26-008994 | EDGAR | 16K words |
| 2025-12-03 | 0001493152-25-025966 | EDGAR | — |
| 2025-11-19 | 0001493152-25-024273 | EDGAR | — |
| 2025-10-15 | 0001493152-25-018156 | EDGAR | — |
| 2025-09-18 | 0001493152-25-013968 | EDGAR | — |
| 2025-07-28 | 0001641172-25-021100 | EDGAR | — |
| 2025-07-16 | 0001641172-25-019856 | EDGAR | — |
| 2025-07-09 | 0001641172-25-018403 | EDGAR | — |
| 2025-06-25 | 0001641172-25-016388 | EDGAR | — |
| 2025-06-12 | 0001641172-25-014895 | EDGAR | — |
105 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001859007 |
| Ticker | ZVSA |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report